Search
Advertisement
China beats Elon Musk's Neuralink to market with world's first commercial brain implant

China beats Elon Musk's Neuralink to market with world's first commercial brain implant

Developed by researchers at Tsinghua University and Shanghai-based Neuracle Medical Technology, the device is designed to help patients suffering from paralysis and spinal cord injuries regain control of hand movements and external devices through brain signals

Business Today Desk
Business Today Desk
  • Updated Jun 16, 2026 1:03 PM IST
China beats Elon Musk's Neuralink to market with world's first commercial brain implantChina has approved NEO, a brain-computer interface for use beyond clinical trials in patients with paralysis caused by spinal cord injuries. (Image created using AI by Divya Bhati)

China has leaped ahead in the global race for neurotechnology, securing the world’s first commercial approval for an invasive brain-computer interface (BCI). The device, named NEO, beat Elon Musk’s Neuralink to the market after receiving the green light from Chinese regulators for medical use. 

Developed by Tsinghua University researchers and Shanghai-based Neuracle Medical Technology, NEO is designed to restore hand movements and device control for patients living with paralysis and spinal cord injuries. 

Advertisement

How NEO works 

Unlike traditional invasive implants, NEO adopts a minimally invasive approach. According to The New York Times, the device places electrodes on the brain’s protective membrane rather than penetrating the deep brain tissue itself. This chip captures neural signals and translates them into digital commands, allowing users to operate external assistive technology like robotic hands and rehabilitation gloves. 

MUST READ: Anthropic and White House officials to hold discussions around Claude Fable 5 ban

Clinical trials involved 36 patients over an extended period. Participants — particularly those with quadriplegia from cervical spinal cord injuries — showed significant improvements in motor control and hand-grasping abilities. Regulators noted these advancements substantially enhanced the patients' overall quality of life. 

NEO vs Neuralink 

Advertisement

This commercial rollout marks a major milestone, giving China a first-mover advantage over its US rivals. While Elon Musk’s Neuralink has implanted its N1 chip in more than 20 patients with promising results, the technology remains tied up in the United States regulatory review process and lacks commercial clearance. China’s accelerated regulatory pathway and direct government backing ultimately fast-tracked NEO from the lab to the market. 

ALSO READ: UK PM Keir Starmer set to announce social media ban for children under 16

The risks ahead 

The medical breakthrough comes with sharp caveats. Experts warn that any brain surgery carries inherent physical risks, including: 

  • Bleeding and infection 
  • Tissue inflammation 
  • Damage to surrounding neural structures 

The technology has also ignited fierce debates around cybersecurity, privacy, and ethics. Because BCIs harvest data directly from the human brain, experts have raised alarms over data ownership, surveillance vulnerabilities, and the threat of unauthorized access to sensitive neural information. Researchers are already questioning the long-term ethical guardrails needed as the technology evolves toward thought-based communication and memory enhancement. 

Advertisement

 

ABOUT THE AUTHOR

Business Today Desk
Business Today Desk

Business Today brings you the latest news, views and analysis from the world of finance, economy, markets, corporates, startups, tech, and the digital economy. You can find everything from breaking news to deep dives to immersive essays and more on a variety of subjects across all formats - online, magazine, television, data visualisation, et al.

Published on: Jun 15, 2026 7:14 PM IST